Reactive arthritis after BCG immunotherapy: T cell analysis in peripheral blood and synovial fluid

Rheumatology (Oxford). 2002 Oct;41(10):1119-25. doi: 10.1093/rheumatology/41.10.1119.

Abstract

Objective: To investigate the pathogenic mechanism of reactive arthritis after instillation of Calmette-Guérin bacillus (BCG). Although the clinical features of reactive arthritis after BCG therapy are well described, only a few reports have studied the possible pathogenic mechanisms.

Methods: We analysed by flow cytometry the phenotype and T-cell receptor (TCR) expression of peripheral blood (PB) and synovial fluid (SF) T cells in a patient who developed reactive arthritis (ReA) following intravesical BCG immunotherapy for bladder cancer. The proliferative response of short-term T-cell lines (TCL) from PB of this patient to mycobacterial antigens was tested by bromodeoxyuridine incorporation.

Results: CD4(+) and CD8(+) SF T cells with activated and memory phenotype were observed at the onset of arthritis. We were able to detect BV-restricted expansion of CD8(+) T cells in PB (BV17) and in SF (BV5S1 and BV12). The percentage of PB and SF CD8(+) T cells that expanded diminished when the symptoms remitted. The strongest response of CD4(+) TCL from the patient in vitro was obtained for human hsp-60 in an inversely dose-dependent manner. Very important was the finding that CD8(+) TCL from the patient demonstrated no proliferative response to any antigenic challenge that was reversed after the addition of exogenous interleukin 2.

Conclusion: Although the identity of the stimulating antigen that led to the expansions observed in this patient is not clarified by the present data, both CD4(+) and CD8(+) T cells might play a role in the development of ReA following intravesical administration of BCG.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arthritis, Reactive / etiology*
  • Arthritis, Reactive / immunology
  • CD4-CD8 Ratio
  • Cell Division
  • Cell Line
  • Humans
  • Immunoglobulin Variable Region
  • Immunophenotyping
  • Immunotherapy / adverse effects*
  • In Vitro Techniques
  • Male
  • Middle Aged
  • Mycobacterium bovis*
  • Prohibitins
  • Receptors, Antigen, T-Cell, alpha-beta / analysis
  • Synovial Fluid / cytology
  • Synovial Fluid / immunology
  • T-Lymphocyte Subsets / chemistry
  • T-Lymphocyte Subsets / cytology*
  • Tuberculin / administration & dosage
  • Urinary Bladder Neoplasms / therapy*

Substances

  • Immunoglobulin Variable Region
  • PHB2 protein, human
  • Prohibitins
  • Receptors, Antigen, T-Cell, alpha-beta
  • Tuberculin